Luteinizing hormone releasing hormone agonists: the US experience

Area of Science:

• Oncology
• Endocrinology

Background:

• Prostate cancer treatment historically relied on hormonal therapies like diethylstilbestrol.
• Androgen deprivation therapy is a cornerstone in managing advanced prostate cancer.

Purpose of the Study:

• To evaluate the efficacy and safety of leuprorelin in prostate cancer treatment.
• To assess the effectiveness of combination therapy with leuprorelin and flutamide for prostate cancer.

Main Methods:

• A large multicentre trial compared leuprorelin with diethylstilbestrol.
• A randomized, double-blind study involving 603 patients compared leuprorelin plus flutamide versus leuprorelin plus placebo.

Main Results:

• Leuprorelin demonstrated comparable efficacy to diethylstilbestrol with a better side-effect profile.
• Combination therapy with leuprorelin and flutamide proved more effective than monotherapy or orchidectomy.
• Progression-free and overall survival were significantly prolonged in the combination therapy group.
• Tumor flare-up and other adverse events were reduced with combination therapy.

Conclusions:

• Leuprorelin is an effective treatment for prostate cancer with an improved safety profile.
• Combination androgen blockade using leuprorelin and flutamide offers superior outcomes for advanced prostate cancer patients.
• This combination therapy improves survival and reduces side effects, including tumor flare-up.